We have established that "massive discounts" really isn't the case when there is no guarantee these other countries will even get the drug. Again, what is the discount when this is the case:But if the company needs $X/drug to make it worth while to do all the R and D on the drug, etc....then the cost to the U.S. should be proportional to the usage of that drug in the country. We should not be giving massive discounts to other countries.
Access to the best new treatments is a postcode lottery, subject to national and regional health-system rules, pricing and reimbursement negotiations, drug companies’ launch plans and the ability of local health care to deliver new treatments.
It’s a complex web of barriers that, at every turn, delays access to sometimes life-saving medicines. And it’s often the least wealthy countries that face the longest delays.
This looks "proportional" to me. You, at least, get to read the data and determine whether it's efficacy meets your requirement to prescribe. You, as a physician, get to determine whether the data makes sense enough to try for a patient.......NOT so in the EU (or Canada). And yet, the EU experiment appears to be what providers want here. More govt control of "care". Insanity.